11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Bioreductive activation of quinone antitumor drugs by mitochondrial voltage-dependent anion channel 1.

      Anatomical Science International

      Antineoplastic Agents, metabolism, Apoptosis, physiology, Cell Line, Doxorubicin, HeLa Cells, Humans, Hydrogen Peroxide, Mitochondria, Mitomycin, NAD, Naphthoquinones, Oxidation-Reduction, Quinones, Vitamin K 3, Voltage-Dependent Anion Channel 1

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The authors recently demonstrated that the mitochondrial voltage-dependent anion channel 1 (VDAC1) is involved in the sensitivity of cancer cells to furanonaphthoquinone (FNQ). The aim of the present study was to investigate whether mitochondrial VDAC1 reduces quinone antitumor drugs. The VDAC1 purified by immunoprecipitation reduced FNQ in the presence of nicotinamide adenine dinucleotide (NADH) and produced H(2)O(2). Blue native polyacrylamide gel electrophoresis demonstrated that the band that reduced FNQ NADH-dependently mainly included VDAC1. Because H(2)O(2) generation in catalyzing FNQ with NADH caused mitochondrial damage, the cytotoxic activity of FNQ was induced by VDAC1. In the quinone antitumor drugs, menadione (VK3), adriamycin and mitomycin C, mitochondrial VDAC1 bioreductively activated VK3. These results demonstrate that mitochondrial VDAC1 is a pharmacologic target for the treatment of tumor.

          Related collections

          Author and article information

          Journal
          19159355
          10.1111/j.1447-073X.2008.00241.x

          Comments

          Comment on this article